Liver Cirrhosis – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Liver Cirrhosis – Drugs In Development, 2023’, provides an overview of the Liver Cirrhosis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Liver Cirrhosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Cirrhosis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Liver Cirrhosis
- The report reviews pipeline therapeutics for Liver Cirrhosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Liver Cirrhosis therapeutics and enlists all their major and minor projects
- The report assesses Liver Cirrhosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Liver Cirrhosis
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Liver Cirrhosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Liver Cirrhosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
4P-Pharma SAS89bio Inc
Akero Therapeutics Inc
Am Sciences
Ascletis Pharma Inc
Asia Cell Therapeutics (Shanghai) Co Ltd
Asia Stem Cell Regenerative Pharmaceutical Co Ltd
Avolynt Inc
Baylx Inc
Bioxytran Inc
BLR Bio LLC
Boehringer Ingelheim International GmbH
Brillian Pharma Inc.
Calliditas Therapeutics AB
CAMP4 Therapeutics Corp
Cascade Pharmaceuticals Inc
Cellaion SA
CellionBioMed Inc
CELLnLIFE Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Cour Pharmaceuticals Development Co Inc
Curamys Co Ltd
Curevac NV
Curigin Co Ltd
CymaBay Therapeutics Inc
Diapin Therapeutics LLC
Dr. Falk Pharma GmbH
Enterobiotix Ltd
Everfront Biotech Inc
Ferring International Center SA
Future Medicine Co Ltd
G&P Bioscience Co Ltd
Galectin Therapeutics Inc
Galecto Inc
Genfit SA
GentiBio Inc
Gilead Sciences Inc
Grifols SA
Guangdong Raynovent Biotech Co Ltd
Guangzhou BeBetter Medicine Technology Co Ltd
Gwoxi Stem Cell Applied Technology Co Ltd
Hanmi Pharmaceuticals Co Ltd
Hepion Pharmaceuticals Inc
HighTide Therapeutics Inc
Hoverink Biotechnologies Inc
Ildong Pharmaceutical Co Ltd
Indiana University School of Medicine
Intercept Pharmaceuticals Inc
International Stem Cell Corp
Invea Therapeutics Inc
INVENT Pharmaceuticals Inc
Inventiva SA
Ipsen SA
Kowa Co Ltd
Lipocine Inc
MD Healthcare Inc
MediGene AG
MetiMedi Pharmaceuticals Co Ltd
Mirum Pharmaceuticals Inc
NGM Biopharmaceuticals Inc
Novo Nordisk AS
Ochre Bio Ltd
Ohara Pharmaceutical Co Ltd
Oncocross Co Ltd
Parvus Therapeutics Inc
Pharmicell Co Ltd
ReCerise Therapeutics Inc
Rejuvenation Technologies Inc
Resolution Therapeutics Ltd
Rohto Pharmaceutical Co Ltd
Sagimet Biosciences Inc
Seoul National University
Shaanxi Micot Technology Co Ltd
Shahid Beheshti University of Medical Sciences
Shanghai Henlius Biotech Inc
Shanghai Huicun Medical Technology Co Ltd
Shionogi & Co Ltd
Shulan (Hangzhou) Hospital
Sihuan Pharmaceutical Holdings Group Ltd
STEMON Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
TenNor Therapeutics Ltd
Therabest Co Ltd
Umecrine Cognition AB
VCANBIO Cell and Gene Engineering Corp Ltd
Vedanta Biosciences Inc
VESSL Therapeutics Ltd
Xiamen Boruilai Pharmaceutical Technology Co Ltd
Zydus Lifesciences Ltd